[go: up one dir, main page]

NI201000197A - 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6 - {[1- (N-METHYLCARBAMOYLMEthyl) PIPERIDIN-4-IL] OXY} QUINAZOLINE DIFFUMARATE SALT. - Google Patents

4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6 - {[1- (N-METHYLCARBAMOYLMEthyl) PIPERIDIN-4-IL] OXY} QUINAZOLINE DIFFUMARATE SALT.

Info

Publication number
NI201000197A
NI201000197A NI201000197A NI201000197A NI201000197A NI 201000197 A NI201000197 A NI 201000197A NI 201000197 A NI201000197 A NI 201000197A NI 201000197 A NI201000197 A NI 201000197A NI 201000197 A NI201000197 A NI 201000197A
Authority
NI
Nicaragua
Prior art keywords
methylcarbamoylmethyl
fluoroanilino
piperidin
oxy
chloro
Prior art date
Application number
NI201000197A
Other languages
Spanish (es)
Inventor
Alison Boardman Kay
Elizabeth Burns Susan
Hornby Dobson Andrew
Whitlock Brian
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40935682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201000197(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NI201000197A publication Critical patent/NI201000197A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Difumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamoilmetil) piperidin - 4 - il] oxi} quinazolina, composiciones farmacéuticas que contienen el difumarato, el uso del difumarato en el tratamiento de trastornos hiperproliferativos como el cáncer y procesos para la fabricación del difumarato son descritos.4- (3-Chloro-2-fluoroanilino) -7-methoxy-6 - {[1- (n-methylcarbamoylmethyl) piperidin-4-yl] oxy} quinazoline difumarate, pharmaceutical compositions containing the difumarate, use of difumarate in the treatment of hyperproliferative disorders such as cancer and processes for the manufacture of difumarate are described.

NI201000197A 2008-05-13 2010-11-15 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6 - {[1- (N-METHYLCARBAMOYLMEthyl) PIPERIDIN-4-IL] OXY} QUINAZOLINE DIFFUMARATE SALT. NI201000197A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5270608P 2008-05-13 2008-05-13
US11063708P 2008-11-03 2008-11-03

Publications (1)

Publication Number Publication Date
NI201000197A true NI201000197A (en) 2012-11-07

Family

ID=40935682

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000197A NI201000197A (en) 2008-05-13 2010-11-15 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6 - {[1- (N-METHYLCARBAMOYLMEthyl) PIPERIDIN-4-IL] OXY} QUINAZOLINE DIFFUMARATE SALT.

Country Status (30)

Country Link
US (2) US8088782B2 (en)
EP (1) EP2303276B1 (en)
JP (1) JP5739802B2 (en)
KR (1) KR20110014192A (en)
CN (1) CN102088979B (en)
AR (1) AR071714A1 (en)
AU (1) AU2009247782C1 (en)
BR (1) BRPI0912170A2 (en)
CA (1) CA2723989C (en)
CL (1) CL2009001159A1 (en)
CO (1) CO6321256A2 (en)
CR (1) CR11791A (en)
CU (1) CU23927B1 (en)
DO (1) DOP2010000346A (en)
EA (1) EA019183B1 (en)
EC (1) ECSP10010610A (en)
ES (1) ES2444128T3 (en)
HN (1) HN2010002408A (en)
IL (1) IL209199A0 (en)
MX (1) MX2010012442A (en)
MY (1) MY183041A (en)
NI (1) NI201000197A (en)
NZ (1) NZ589883A (en)
PE (1) PE20091970A1 (en)
SA (1) SA109300290B1 (en)
SV (1) SV2010003734A (en)
TW (1) TWI443095B (en)
UY (1) UY31820A (en)
WO (1) WO2009138781A1 (en)
ZA (1) ZA201008283B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
MX2011011177A (en) * 2009-04-23 2011-11-18 Astrazeneca Ab Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-me thoxy-6-[1-(n-methylcarbamoylmethyl)-piperidin-4-yl]quinazoline.
JP2015524400A (en) * 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Fumarate salt of 9- [4- (3-chloro-2-fluoro-phenylamino) -7-methoxy-quinazolin-6-yloxy] -1,4-diaza-spiro [5.5] undecan-5-one , Its use and preparation as drugs
JP6769962B2 (en) * 2014-12-03 2020-10-14 オークランド ユニサービシーズ リミティド Kinase inhibitor prodrugs for cancer treatment
WO2019196619A1 (en) * 2018-04-08 2019-10-17 威尚（上海）生物医药有限公司 Quinazoline derivative salt-form crystal form, and preparation method therefor and application thereof
CN109384747A (en) * 2018-10-26 2019-02-26 苏州立新制药有限公司 Gefitinib related substances and its preparation and detection method
WO2022170052A1 (en) * 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985749A (en) * 1975-12-22 1976-10-12 Eastman Kodak Company Process for preparation of 4-aminoquinazoline
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4332420A (en) 1980-01-11 1982-06-01 Coski William D Reciprocably supported dual drive member and features thereof
US4456359A (en) 1981-11-04 1984-06-26 Ciba-Geigy Ag Flat photographic sheet processing cassette
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
KR910006138B1 (en) 1986-09-30 1991-08-16 에자이 가부시끼가이샤 Cyclic amine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5252586A (en) * 1990-09-28 1993-10-12 The Du Pont Merck Pharmaceutical Company Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents
DE4105503A1 (en) 1991-02-19 1992-08-20 Jenapharm Gmbh INITIAL COMPOUNDS FOR THE PRODUCTION OF CALCITRIOL AND ITS COLLECTING MATERIALS, METHOD FOR THE PRODUCTION OF THESE OUTPUT CONNECTIONS AND INTERMEDIATE PRODUCTS FOR THIS PROCESS
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
ES2108120T3 (en) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int MONO- AND BICYCLE BIS ARYLIC AND HETEROARILIC COMPOUNDS INHIBITING EGF AND / OR PDGF TYPHOSINE KINASE.
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0517394B1 (en) * 1991-06-04 1995-06-28 Fujisawa Pharmaceutical Co., Ltd. A prophylactic/therapeutic composition for swine pleuropneumonia
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
PT100905A (en) 1991-09-30 1994-02-28 Eisai Co Ltd BICYCLE HYGIENEOUS HETEROCYCLIC COMPOUNDS CONTAINING BENZENE, CYCLOHEXAN OR PYRIDINE AND PYRIMIDINE, PYRIDINE OR IMIDAZOLE SUBSTITUTES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
CA2163747C (en) 1993-05-26 2007-01-30 Robin Douglas Clark Novel 1-phenylalkanone 5-ht4 receptor ligands
US5395846A (en) 1993-06-25 1995-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
AU2096895A (en) 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
ATE205483T1 (en) 1995-03-30 2001-09-15 Pfizer QUINAZOLINE DERIVATIVES
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
WO1996033977A1 (en) 1995-04-27 1996-10-31 Zeneca Limited Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
WO1997011692A2 (en) 1995-09-11 1997-04-03 Osteoarthritis Sciences, Inc. Protein tyrosine kinase inhibitors for treating osteoarthritis
JP2000500502A (en) 1995-11-22 2000-01-18 メルク エンド カンパニー インコーポレーテッド Farnesyl-protein transferase inhibitor
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0817613B1 (en) * 1996-01-31 2005-03-30 Cosmoferm B.V. Use of compositions comprising stabilized enzymes
US6262054B1 (en) * 1996-02-01 2001-07-17 Sloan-Kettering Institute Of Cancer Research Combination therapy method for treating breast cancer using edatrexate
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DE69709319T2 (en) 1996-03-05 2002-08-14 Astrazeneca Ab, Soedertaelje 4-ANILINOQUINAZOLINE DERIVATIVES
ES2174250T5 (en) 1996-04-12 2010-04-21 Warner-Lambert Company Llc IRREVERSIBLE THYROSINE KINASE INHIBITORS.
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
GB9626589D0 (en) * 1996-12-20 1997-02-05 Prolifix Ltd Peptides
JP4713698B2 (en) 1997-03-05 2011-06-29 スージェン， インク． Formulation of hydrophobic drugs
AR012634A1 (en) 1997-05-02 2000-11-08 Sugen Inc QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
EP0980244B1 (en) 1997-05-06 2003-06-04 Wyeth Holdings Corporation Use of quinazoline compounds for the treatment of polycystic kidney disease
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
WO1999010349A1 (en) 1997-08-22 1999-03-04 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
CA2306155A1 (en) 1997-11-06 1999-05-20 Philip Frost Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
JP4245682B2 (en) 1997-12-25 2009-03-25 協和発酵キリン株式会社 Quinoline derivatives, isoquinoline derivatives, and cinnoline derivatives, and anti-inflammatory and anti-allergic agents
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CA2333392A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
AU4851599A (en) 1998-06-30 2000-01-17 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
DE69928262D1 (en) 1998-07-30 2005-12-15 Wyeth Corp SUBSTITUTED CHINAZOLINE DERIVATIVES
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
AU5195999A (en) 1998-08-11 2000-03-06 Takeda Chemical Industries Ltd. Cyclic amide compounds, process for producing the same, intermediates thereof and herbicides
HUP0103386A3 (en) 1998-08-21 2002-07-29 Parker Hughes Inst St Paul Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP1950201A1 (en) 1998-09-29 2008-07-30 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
JP2002526538A (en) 1998-10-01 2002-08-20 アストラゼネカ アクチボラグ Chemical compound
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EE05345B1 (en) 1999-02-10 2010-10-15 Astrazeneca Ab Quinazoline derivatives as inhibitors of angiogenesis
TR200102505T2 (en) * 1999-02-27 2003-01-21 Boehringer Ingelheim Pharma Kg 4-amino-quinazoline and quinoline derivatives.
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DE19911509A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE19911510A1 (en) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
AU3630100A (en) 1999-03-19 2000-10-09 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
EP1182195A4 (en) * 1999-05-07 2003-03-26 Takeda Chemical Industries Ltd CYCLIC COMPOUNDS AND THEIR USES
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
CA2375259C (en) 1999-06-21 2009-04-28 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
IL147280A0 (en) 1999-07-07 2002-08-14 Astrazeneca Uk Ltd Quinazoline derivatives
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
NZ517120A (en) 1999-08-12 2004-10-29 Wyeth Corp NSAID and EFGR kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
EP1218356A1 (en) 1999-09-21 2002-07-03 AstraZeneca AB Quinazoline compounds and pharmaceutical compositions containing them
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
KR100881105B1 (en) 1999-11-05 2009-02-02 아스트라제네카 아베 Quinazolin Derivatives as VEGF Inhibitors
JP2003518023A (en) 1999-11-30 2003-06-03 パーカー ヒューズ インスティテュート Inhibitors of thrombin-induced platelet aggregation
DE60112268T2 (en) 2000-03-06 2006-05-24 Astrazeneca Ab USE OF QUINAZOLIN DERIVATIVES AS INHIBITORS OF ANGIOGENESIS
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20030152572A1 (en) * 2000-04-06 2003-08-14 Yoshimi Homma Diagnostic and therapeutic agents for rheumatoid arthritis
DE60121931T2 (en) 2000-04-07 2007-03-01 Astrazeneca Ab quinazoline
WO2001087293A1 (en) 2000-05-19 2001-11-22 Takeda Chemical Industries, Ltd. -secretase inhibitors
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
AU2001278609B2 (en) 2000-08-21 2005-04-14 Astrazeneca Ab Quinazoline derivatives
US6617329B2 (en) * 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
DE10042062A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and methods of preparation
DE10042058A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10042061A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
US6740651B2 (en) * 2000-08-26 2004-05-25 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042059A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10042060A1 (en) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
US6656946B2 (en) * 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE60119939T2 (en) 2000-09-21 2006-11-30 Smithkline Beecham P.L.C., Brentford CHINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS
JP2004511479A (en) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ Quinazoline derivatives
NZ526003A (en) 2000-10-20 2005-09-30 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
EP1332141A1 (en) 2000-10-25 2003-08-06 AstraZeneca AB Quinazoline derivatives
US20030158196A1 (en) * 2002-02-16 2003-08-21 Boehringer Ingelheim Pharma Gmbh Co. Kg Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
EP1337524A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB Substituted quinolines as antitumor agents
HUP0400683A2 (en) * 2000-12-11 2004-06-28 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability containing her2 inhibitor
AUPR201600A0 (en) 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10063435A1 (en) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazoline derivatives, pharmaceuticals containing these compounds, their use and process for their preparation
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
WO2002062767A1 (en) 2001-02-07 2002-08-15 Sumitomo Pharmaceuticals Company, Limited Novel quinazoline derivatives
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
WO2002066445A1 (en) 2001-02-21 2002-08-29 Mitsubishi Pharma Corporation Quinazoline derivatives
DE60210944T3 (en) 2001-02-23 2015-07-23 Merck Sharp & Dohme Corp. N-SUBSTITUTED NONARYL HETEROCYCLIC NMDA / NR2B ANTAGONISTS
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
PE20021011A1 (en) 2001-03-23 2003-02-01 Bayer Corp QUINAZOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
AR033765A1 (en) 2001-05-22 2004-01-07 Syngenta Participations Ag PROCEDURE FOR THE PREPARATION OF DERIVATIVES 3-ALQUIL-3H-ISOBENZOFURAN-1-ONA 7-SUBSTITUTES.
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc Novel quinazolines and uses thereof
WO2003040108A1 (en) 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0128109D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
CN1602195A (en) 2001-12-12 2005-03-30 辉瑞产品公司 Quinazoline derivatives for the treatment of abnormal cell growth
JP2003246780A (en) 2001-12-17 2003-09-02 Eisai Co Ltd Method for manufacturing aromatic ring compound containing nitrogen
MXPA04007459A (en) 2002-02-01 2005-09-08 Astrazeneca Ab Quinazoline compounds.
DE10204462A1 (en) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
US20050130995A1 (en) * 2002-02-06 2005-06-16 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
WO2003082290A1 (en) * 2002-03-30 2003-10-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) * 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
WO2003101491A1 (en) * 2002-06-03 2003-12-11 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
CN1192564C (en) * 2002-06-06 2005-03-09 华为技术有限公司 Method for opening grouping updating of fifth group link state notice of shortest route priority procotol
US6900206B2 (en) * 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
AT6168U1 (en) * 2002-07-15 2003-05-26 Blum Gmbh Julius HINGE
CA2480668C (en) 2002-08-19 2009-11-24 Art Jen Complexus, Inc. Compositions comprising dietary fat complexer and methods for their use
KR100942073B1 (en) * 2002-08-23 2010-02-12 기린 홀딩스 가부시키가이샤 Compound having TVF β inhibitory activity and pharmaceutical composition comprising the same
JPWO2004060400A1 (en) * 2003-01-06 2006-05-11 那波　宏之 Antipsychotic drug targeting epidermal growth factor receptor
DE10300097A1 (en) * 2003-01-07 2004-07-22 Bayer Ag Copper complexes and their use
DE10300098A1 (en) * 2003-01-07 2004-07-15 Bayer Ag Copper-carbene complexes and their use
WO2004064718A2 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
DE10315917A1 (en) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Highly pure bases of 3,3-diphenylpropylamine monoesters
GB0309009D0 (en) 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
BRPI0413066A (en) * 2003-07-29 2006-10-17 Astrazeneca Ab quinazoline derivative, or a pharmaceutically acceptable salt, or a pharmaceutically acceptable ester thereof, of formula I, use and process for the preparation thereof, compound, pharmaceutical composition, and methods for producing an antiproliferative effect in an animal of warm blood, for the prevention or treatment of a tumor, to provide a selective egfr tyrosine kinase inhibitory effect, and to treat cancer in a warm-blooded animal
ATE395346T1 (en) 2003-09-16 2008-05-15 Astrazeneca Ab QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
GB0321648D0 (en) 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US20070032508A1 (en) 2003-09-16 2007-02-08 Bradbury Robert H Quinazoline derivatives as tyrosine kinase inhibitors
ATE352550T1 (en) * 2003-09-19 2007-02-15 Astrazeneca Ab CHINAZOLINE DERIVATIVES
ATE353888T1 (en) * 2003-09-19 2007-03-15 Astrazeneca Ab CHINAZOLINE DERIVATIVES
JP2007506716A (en) * 2003-09-25 2007-03-22 アストラゼネカ アクチボラグ Quinazoline derivatives
AR051444A1 (en) * 2004-09-24 2007-01-17 Centocor Inc PROTEINS DERIVED FROM IL-23P40 SPECIFIC IMMUNOGLOBULIN, COMPOSITIONS, EPITHOPES, METHODS AND USES
CA2617327A1 (en) * 2005-08-04 2007-02-15 Novartis Ag Salts of vildagliptin
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
KR20080028813A (en) * 2006-09-27 2008-04-01 삼성전자주식회사 Apparatus and method for pilot channel discovery control in communication system

Also Published As

Publication number Publication date
EA019183B1 (en) 2014-01-30
CN102088979A (en) 2011-06-08
AR071714A1 (en) 2010-07-07
ES2444128T3 (en) 2014-02-24
CO6321256A2 (en) 2011-09-20
DOP2010000346A (en) 2011-01-15
US20090286982A1 (en) 2009-11-19
CN102088979B (en) 2013-10-16
SA109300290B1 (en) 2013-05-18
ZA201008283B (en) 2011-08-31
SV2010003734A (en) 2011-03-15
EA201001773A1 (en) 2011-06-30
TW201008923A (en) 2010-03-01
MX2010012442A (en) 2011-10-11
EP2303276B1 (en) 2013-11-13
CU20100222A7 (en) 2011-11-15
CU23927B1 (en) 2013-07-31
CA2723989C (en) 2017-04-25
US20120035363A1 (en) 2012-02-09
US8088782B2 (en) 2012-01-03
PE20091970A1 (en) 2010-02-05
AU2009247782C1 (en) 2013-09-19
WO2009138781A1 (en) 2009-11-19
ECSP10010610A (en) 2010-12-30
MY183041A (en) 2021-02-08
BRPI0912170A2 (en) 2015-10-13
EP2303276A1 (en) 2011-04-06
AU2009247782B2 (en) 2012-06-28
CL2009001159A1 (en) 2010-06-11
JP5739802B2 (en) 2015-06-24
NZ589883A (en) 2012-06-29
KR20110014192A (en) 2011-02-10
UY31820A (en) 2010-01-05
US8404839B2 (en) 2013-03-26
JP2011520857A (en) 2011-07-21
IL209199A0 (en) 2011-01-31
CR11791A (en) 2011-01-12
AU2009247782A1 (en) 2009-11-19
CA2723989A1 (en) 2009-11-19
TWI443095B (en) 2014-07-01
HK1152867A1 (en) 2012-03-16
HN2010002408A (en) 2013-05-06

Similar Documents

Publication Publication Date Title
CU20120042A7 (en) (HETEROARILMETIL) SUBSTITUTED THIOHYDANTOINS AS ANTI-CANCER DRUGS
CL2008001374A1 (en) Compounds derived from pyrazolo pyrimidines, inhibitors of pde9; pharmaceutical composition comprising said compounds; Useful in the treatment of a neurodegenerative and cognitive disorder such as Alzheimer's disease and schizophrenia.
NI201000197A (en) 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6 - {[1- (N-METHYLCARBAMOYLMEthyl) PIPERIDIN-4-IL] OXY} QUINAZOLINE DIFFUMARATE SALT.
CR20140161A (en) BENZILINDAZOLS REPLACED FOR USE AS INHIBITORS OF QUINASA BUB1 IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
CL2008002097A1 (en) Compounds derived from substituted fused heterocycles, phosphatidyl-inositol-3 kinase inhibitors; pharmaceutical composition; and use in the treatment of cancer.
CL2012000163A1 (en) Compounds derived from quinazoline or pyrido [2,3-d] pyrimidine, autophagy inhibitors; pharmaceutical composition; and its use for the treatment of cancer, pancreatitis, neurodegeneration, among others.
SV2011003855A (en) HETEROARILOS SUBSTITUTED
CR20120510A (en) DERIVATIVES OF PIPERIDIN-4-IL AZETIDINE AS INHIBITORS OF JAK1
CL2011003147A1 (en) Compounds derived from n- (1-4- (1h-pyrazol-5-yl) phthalazine-1-yl) piperidine-4-yl) benzamide; pharmaceutical composition that contains them, useful as antagonist of the hedgehog trajectory, in the treatment of cancer.
CL2007002316A1 (en) COMPOUNDS DERIVED FROM PYRIMIDINE, PI3K INHIBITORS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN PROLIFERATIVE DISEASES AS CANCER.
MX361467B (en) Isoindoline compounds for use in the treatment of cancer.
MX2013001970A (en) PIRROLOPIRIMIDINE COMPOUNDS AND USES OF THE SAME.
ECSP088210A (en) SUBSTITUTED BENCIMIDAZOLS AND PREPARATION METHODS
CL2007002994A1 (en) HETEROCICLIC DERIVATIVE COMPOUNDS CONTAINING SULFAMOIL, INHIBITORS OF HSP90; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER, SUCH AS CANCER OF BREAST, COLON AND PROSTATE, BETWEEN OTHERS.
CL2008001373A1 (en) Compounds derived from substituted phenylamino-benzene; Preparation method; pharmaceutical composition; farm kit; and use of said compounds in the treatment of cancer.
PE20121617A1 (en) OXAZINE DERIVATIVES AS BACE INHIBITORS
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
CL2008000875A1 (en) COMPOUNDS DERIVED FROM IMIDAZOLIDIN-2-ONA; OBTAINING PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND / OR PROFILAXIS OF DISEASES SUCH AS DYSLIPIDEMIA, DIABETES, INFLAMMATORY DISEASES, AMONG OTHERS.
CO6470899A2 (en) 2,4-DIAMINOPIRIMIDINES FOR THE TREATMENT OF CHARACTERIZED DISEASES BY EXCESSIVE OR NORMAL CELL PROLIFERATION
BR112015006524A2 (en) quinazolinone derivatives as parp inhibitors
AR059320A1 (en) ANTITUMORIAL COMPOSITION THAT INCLUDES AN INHIBITOR OF CYCLINE DEPENDENT KINASES AND AN ANTIBODY THAT INHIBITS A GROWTH FACTOR AND / OR AN ANTIMITOTIC COMPOUND
UY29092A1 (en) DERIVATIVES OF 4-OXO-3,4-DIHIDROQUINAZOLIN-6-CARBOXAMIDA, B-RAF INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS
CL2008001322A1 (en) Compounds derived from triazolyl-aminopyrimidine, substituted with heterocycles; pharmaceutical composition; and use in the treatment of cancer.
UY29398A1 (en) DERIVATIVES OF QUINAZOLINAS, PHARMACEUTICALLY ACCEPTABLE SUSSALES, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS.
UA103998C2 (en) 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate